You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here

CRONOS-II

Evaluation of Diet and Exercise in Prostate Cancer Patients

    Status Recruiting
    Related Conditions
    Prostate Cancer

Enrollment Details

1300 Worldwide Enrollment Goal

Phases: 

  • 1
  • 2
  • 3
  • 4
Study Type:  Observational

This is a type IV phase trial.

Protocol ID
P14-096

Brief summary

Top

Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients Managed with Lupron.

Participant Attributes :
  • Male
  • Ages 18 Years to 99 Years

Canada: 50

0
Abbotsford, BC
1
Kelowna, BC
2
Victoria, BC
3
Winnipeg, MB
4
Saint John, NB
5
Halifax, NS
6
Barrie, ON
7
Barrie, ON
8
Belleville, ON
9
Brampton, ON
10
Brantford, ON
11
Burlington, ON
12
Burlington, ON
13
Hamilton, ON
14
Kingston, ON
15
London, ON
16
Markham, ON
17
Newmarket, ON
18
North York, ON
19
Oakville, ON
20
Ottawa, ON
21
Ottawa, ON
22
Peterborough, ON
23
Peterborough, ON
24
Richmond Hill, ON
25
Scarborough, ON
26
Scarborough, ON
27
Scarborough, ON
28
Sudbury, ON
29
Toronto, ON
30
Toronto, ON
31
Toronto, ON
32
Toronto, ON
33
Toronto, ON
34
Chicoutimi, QC
35
Gatineau, QC
36
Greenfield Park, QC
37
Greenfield Park, QC
38
Greenfield Park, QC
39
Laval, QC
40
Laval, QC
41
Montreal, QC
42
Montreal, QC
43
Montréal, QC
44
Pointe-Claire, QC
45
Sherbrooke, QC
46
Trois-Rivieres, QC
47
Trois-Rivières, QC
48
Val D'Or, QC
49
Westmount, QC
Would you like to know more about this trial?

Study Design

  • The general design that describes the strategy for identifying and following up with participants during observational studies.
    ?

    Observational Model

    Cohort

  • The relationship between the observation period and the time of patient enrollment. Time perspective can be prospective: looking forward using periodic observations usually collected following patient enrollment, or retrospective: looking back using observations usually collected prior to patient selection and enrollment.
    ?

    Time Perspective

    Prospective

    • Adult ≥ 18 years old.
    • Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel.
    • Diagnosed with PCa.
    • Prescribed Lupron as part of his treatment by his treating physician.
    • Patient cannot or will not sign informed consent.
    • Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of PCa.
    • Survival expectancy less than 2-3 years as per the treating physician judgment
    • More than 6 months of therapy if currently on continuous Luteinizing hormone-releasing hormone (LHRH) treatment.
    • If at study enrollment the intent is to only prescribe 1 dose of Lupron (leuprolide acetate)

More on this trial

Clinical Trials.gov